Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. slides, 8-K earnings release, 8-K call announcement, 10-Q stay in one workspace.
INDV
$35.75
+1.05%
INDV
· Indivior Pharmaceuticals, Inc.
$35.75
+0.37 (+1.05%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$4.23B
Shares
118.01M
Volume · Oct 1
1.88M
Avg daily vol (3M)
2.04M
All webcasts
Earnings call · FY2026 Q2
Indivior Pharmaceuticals, Inc. (INDV) Q2 2026 Earnings Call
Forward guidance
2 guided metrics
Management's latest ranges and targets are included below.
Research coverage
4 live sources
Open each available source without leaving this research workspace.
Revenue
$343.00M
+13.6% YoY
Diluted EPS
$0.98
+600% YoY
Gross margin
85.7%
+2.9 pp YoY
Net income
$122.00M
+577.8% YoY
Research materials
Open the source you need; every reader stays inside this workspace.
Forward guidance
From the 8-K filed Aug 3, 2026.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Adjusted EBITDA
table
Initiated
Full-year 2026
|
$700M – $740M | Non-GAAP | |
|
Cash flow from operations
2026
|
$420M | — |
Quarter detail
How the reported period landed and where the business moved.
Company presentation
Slides
25 pages · use arrow keys or swipe to navigate
SEC filing · Item 2.02
8-K earnings release
Filed Aug 3, 2026 · complete as-filed document
SEC periodic report
10-Q report
Filed Aug 3, 2026 · complete as-filed document
SEC call announcement
8-K call announcement
Filed Aug 3, 2026 · complete as-filed document